FTC: Shkreli could have violated lifetime pharma ban, ought to be held in contempt

Martin Shkreli, former CEO of Turing, smirked his way through a congressional hearing.

Enlarge / Martin Shkreli, former CEO of Turing, smirked his manner by a congressional listening to. (credit score: CSPAN)

Notorious ex-pharmaceutical govt Martin Shkreli is but once more in bother with the Federal Commerce Fee, which introduced right now that the convicted fraudster has didn’t cooperate with the fee’s investigation into whether or not he violated his lifetime ban from the pharmaceutical trade by beginning an organization final 12 months known as “Druglike, Inc.”

In a court docket submitting right now, the FTC requested a federal choose in New York to search out Shkreli in contempt for failing to show over requested paperwork to the FTC and failing to make himself accessible for an interview. Underneath the 2022 court docket order barring him from involvement within the pharmaceutical trade for all times, Shkreli is required to supply such info to the FTC, the fee famous.

“Martin Shkreli’s failure to adjust to the court docket’s order demonstrates a transparent disregard for the legislation,” Holly Vedova, director of the FTC’s Bureau of Competitors, mentioned in a press launch. “The FTC is not going to hesitate to deploy the complete scope of its authorities to allow a complete investigation into any potential misconduct.”

Learn 6 remaining paragraphs | Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *